Bifogade filer
Prostatype Genomics Arsredovisning 2023 SVE
Kurs & Likviditet
Prenumeration
Beskrivning
| Land | Sverige |
|---|---|
| Lista | First North Stockholm |
| Sektor | Hälsovård |
| Industri | Medicinteknik |
Prostatype Genomics AB today publishes the Annual Report for the financial year of 2023. The Annual Report (Swedish) is attached as a PDF and is available on the company's webpage: www.prostatypegenomics.com
The English version of the Annual Report will be available to downloaded from the company’s webpage within shortly.
For more information, please contact:
Fredrik Rickman (previously Persson), CEO Prostatype Genomics AB
Telephone: +46 (0) 73 049 77 01
e-mail: fredrik.persson@prostatypegenomics.com
About Prostatype Genomics AB
Prostatype® is a genetic test that is available to patients and treating urologists as a complementary decision basis for the question of treatment or non-treatment of prostate cancer. The test was developed by a research group at Karolinska Institutet and is provided by Prostatype Genomics AB. The Company’s Certified Adviser is Carnegie Investment Bank AB.